

Case Number:

Patient Name:

Age/Sex:

Patient Location:

Hospital Name:

Physician Name:

Date & Time of Accessioning:

Date & Time of Reporting:

TEST NAME

liquiCORE PIK3CA

SPECIMEN INFORMATION

Peripheral blood in PAX gene tube collected on 08/11/2022.

CLINICAL HISTORY

Carcinoma breast.

METHODOLOGY

Real-Time Polymerase Chain Reaction (RT-PCR)

RESULTS

No mutation detected in the PIK3CA gene

COMMENTS

- 1. This assay helps in identifying breast cancer patients who may be eligible for treatment with PIQRAY® (alpelisib), a-selective PI3K-inhibitor, based on a PIK3CA Mutation Detected result.
- 2. The therascreen PIK3CA RGQ PCR Kit is the first companion diagnostic (CDx) test to be approved by the FDA.
- 3. Mutations in the PIK3CA gene have been identified in carcinomas arising from colon, breast, ovary, liver, stomach, and lung as well as in Glioblastomas.
- 4. Evidence suggests that such mutations lead to constitutive activation of the PI3K pathway.
- 5. Patients whose plasma specimen produces a negative result using this test should be reflexed to testing with FFPE tumor tissue for the presence of possible PIK3CA mutations, if any.



Dr. Bhardwaj Tina Neelesh, Consultant Molecular Biologist Dr. Rahul Katara, Ph.D.

Dr. Shivani Sharma, DCP, DNB Reg. No. 1906

Shiwani





Case Number:

Patient Name:

Age/Sex:

Patient Location:

Hospital Name:

Physician Name:

Date & Time of Accessioning:

Date & Time of Reporting:

TEST INFORMATION

This test covered the following exons/mutations of PIK3CA gene.

Exons	Amino acid change	Base change
7	C420R	1258T>C
9	E542K	1624G>A
	E545A	1634A>C
	E545D	1635G>T
	E545G	1634A>G
	E545K	1633G>A
	Q546E	1636C>G
20	H1047L	3140A>T
	H1047R	3140A>G
	H1047Y	3139C>T

REFERENCES

- 1. Katso, R., Okkenhaug, K., Ahmadi, K., et al. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell. Dev. Biol. 17, 615.
- 2. Samuels, Y., Wang, Z., Bardelli, A., et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science. 304, 554.
- 3. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumors. Nature. 490, 61.



Dr. Bhardwaj Tina Neelesh, Consultant Molecular Biologist Dr. Rahul Katara, Ph.D.

Dr. Shivani Sharma, DCP, DNB Reg. No. 1906

Shirani



Question?

Contact us at +91 124 4615 615

Toll Free Helpline +91 8882899999

CONDITIONS OF REPORTING

- 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.
- 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.
- 3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.
- 4. Some tests are referred to other laboratories to provide a wider test menu to the customer.
- 5. Core Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not attributable to any direct and mala fide act or omission of Core Diagnostics Pvt. Ltd. or its employees. Liability of Core Diagnostics Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

This report is the property of CORE Diagnostics. The information contained in this report is strictly confidential and is only for the use of those authorized. If you have received this report by mistake, please contact CORE Diagnostics

CORE Diagnostics National Reference Lab - Gurugram

406, Udyog Vihar, Phase III, Gurgaon 122016

CORE Diagnostics Satellite Lab - New Delhi

CORE Diagnostics Satellite Lab - Bangalore

C-13, Green Park Extension, New Delhi – 110016

1st Floor, KMK Tower, 142 KH Road, Bangalore - 560027